GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » Effective Interest Rate on Debt %

NVN Liquidation (NVN Liquidation) Effective Interest Rate on Debt % : 28.48% (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. NVN Liquidation's annualized positive value of Interest Expense for the quarter that ended in Mar. 2023 was $1.11 Mil. NVN Liquidation's average total debt for the quarter that ended in Mar. 2023 was $3.89 Mil. Therefore, NVN Liquidation's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2023 was 28.48%.


NVN Liquidation Effective Interest Rate on Debt % Historical Data

The historical data trend for NVN Liquidation's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NVN Liquidation Effective Interest Rate on Debt % Chart

NVN Liquidation Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only 13.05 0.03 - - 38.50

NVN Liquidation Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.36 11.84 20.74 7.71 28.48

Competitive Comparison of NVN Liquidation's Effective Interest Rate on Debt %

For the Biotechnology subindustry, NVN Liquidation's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NVN Liquidation's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NVN Liquidation's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where NVN Liquidation's Effective Interest Rate on Debt % falls into.



NVN Liquidation Effective Interest Rate on Debt % Calculation

NVN Liquidation's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2021 )+Total Debt  (A: Dec. 2022 ))/ count )
=-1  *  -1.452/( (3.613+3.93)/ 2 )
=-1  *  -1.452/3.7715
=38.50 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.739 + 0.191
=3.93

NVN Liquidation's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2022 )+Total Debt  (Q: Mar. 2023 ))/ count )
=-1  *  -1.108/( (3.93+3.852)/ 2 )
=-1  *  -1.108/3.891
=28.48 %

where

Total Debt  (Q: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.739 + 0.191
=3.93

Total Debt  (Q: Mar. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.387 + 0.465
=3.852

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


NVN Liquidation  (OTCPK:NOVNQ) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


NVN Liquidation Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of NVN Liquidation's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


NVN Liquidation (NVN Liquidation) Business Description

Industry
Traded in Other Exchanges
N/A
Address
P.O. Box 64, Pittsboro, NC, USA, 27312
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman director 9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour director C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay officer: VP, Finance & Corp. Controller C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John officer: EVP, Chief Operating Officer C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky director TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin director C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram director 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer director 7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak officer: Chief Accounting Officer C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513